Association of Diabetes Care & Education Specialists

Login
Home Page
Your Personalized Guide
to AADE Resources
AADE GPS
My Profile
My Memberships
My Purchases
MY AADE NETWORK
My Open Invoices
Join Online
Online Store
Events
Make a Donation
Access My Learning
Access AADE7 System
Find a Diabetes Educator
Find an Accredited DSME Program
Apply For/Manage My DEAP Application

Event Profile

Humulin® R U-500 (insulin human injection) 500 units/mL: Could insulin monotherapy be a fresh start for your patients on high-dose* insulin?

May 27, 2021

Location: Online

Website: https://www.diabeteseducator.org/event/WEBI210527


For more information, please see Full Prescribing Information

Event Date: Thursday, May 27, 2021
Event Time: 1:00 - 2:00 pm EST

Please Note: All times are Eastern. Our webinars begin at 1:00 pm Eastern / 12:00 pm Central / 11:00 am Mountain / 10:00 am Pacific.









Description

Humulin R U-500: Could insulin monotherapy be a fresh start for your patients on high-dose* insulin?1 As insulin monotherapy, U-500 provides the properties of both basal and mealtime insulin. U-500 may reduce the number of injections1 to either 2 or 3 injections per day.

This webinar is sponsored by Lilly USA, LLC.

Objectives

After completing this activity, participants will be able to:
-- Identify the long and frustrating journey experienced by patients on high-dose* basal-bolus insulin therapy.
-- Understand the efficacy, benefits, and risks of U-500.
-- Recognize how U-500 monotherapy may reduce the injection burden of the typical basal-bolus regimen.2,3†
-- Discuss how to help patients get off to a good start with U-500.

*>200 units of insulin per day.
Compared to U-100 insulin. For patients taking >200 units of insulin per day.


References
1.  Hood RC, et al. Endocr Pract. 2015;21(7):782-793; Erratum, 2016;22(7):905.
2.  Data on file, Lilly USA, LLC. HI20130603A.
3.  Data on file, Lilly Research Laboratories. HI20130221A.

Intended Audience

This activity is designed for diabetes care and education specialists, including nurses, dietitians, pharmacists, nurse practitioners, clinical nurse specialists, physicians, physician assistants, and other healthcare providers interested in staying up to date on current practices of care for people with diabetes and other related conditions.



INDICATION FOR HUMULIN® R U-500

Humulin R U-500 is a concentrated human insulin indicated to improve glycemic control in adults and children with diabetes mellitus requiring more than 200 units of insulin per day.
Limitations of Use: The safety and efficacy of Humulin R U-500 used in combination with other insulins, or when delivered by continuous subcutaneous infusion, has not been determined.

IMPORTANT SAFETY INFORMATION FOR HUMULIN R U-500

Contraindications
Humulin R U-500 is contraindicated during episodes of hypoglycemia and in patients hypersensitive to Humulin R U-500 or any of its excipients.

Hyperglycemia, Hypoglycemia, or Death Due to Dosing Errors With Vial Presentation

  • Can be life-threatening. Overdose has occurred as a result of dispensing, prescribing, or administration errors. Attention to details at all levels is required to prevent these errors.
  • Patients should be prescribed U-500 syringes for use with Humulin R U-500 vials. Do not use any other type of syringe to administer Humulin R U-500.
  • If using the Humulin R U-500 KwikPen®, patients should be counseled to dial and dose the prescribed number of units of insulin.
  • Do NOT perform dose conversion when using the Humulin R U-500 KwikPen or U-500 insulin syringe.
DO NOT transfer Humulin R U-500 from the KwikPen into any syringe for administration. Overdose and severe hypoglycemia can occur.

Never share a KwikPen or U-500 syringe between patients, even if the needle is changed, to avoid risk of transmission of blood-borne pathogens.

Hyperglycemia or Hypoglycemia With Changes in Insulin Regimen
  • Changes in insulin strength, manufacturer, type, injection site, or method of administration may affect glycemic control and predispose to hypoglycemia or hyperglycemia. Any changes in insulin regimen should be made cautiously and only under close medical supervision, and the frequency of blood glucose monitoring should be increased. Due to reports of hypoglycemia and hyperglycemia, advise patients who have repeatedly injected into areas of lipodystrophy or localized cutaneous amyloidosis to change the injection site to the unaffected areas and to closely monitor blood glucose. For patients with type 2 diabetes, dosage adjustments of concomitant anti-diabetic products may be needed.
Hypoglycemia
  • Hypoglycemia is the most common adverse reaction associated with insulin, including Humulin R U-500. Severe hypoglycemia can cause seizures, may be life-threatening, or cause death.
  • Increase monitoring with changes to insulin dosage, co-administered glucose-lowering medications, meal patterns, physical activity, and in patients with renal or hepatic impairment or hypoglycemia unawareness. To minimize risk of hypoglycemia, do not administer Humulin R U-500 intravenously, intramuscularly, or in an insulin pump or dilute or mix with other products, including other insulins.
  • Patients and caregivers must be educated to recognize and manage hypoglycemia. Self-monitoring of blood glucose plays an essential role in the prevention and management of hypoglycemia. In patients at higher risk for hypoglycemia and patients who have reduced symptomatic awareness of hypoglycemia, increased frequency of blood glucose monitoring is recommended.
Hypersensitivity and Allergic Reactions
  • Severe, life-threatening, generalized allergy, including anaphylaxis, can occur with insulin products, including Humulin R U-500. If hypersensitivity reactions occur, discontinue Humulin R U-500; treat per standard of care and monitor until symptoms and signs resolve.
Hypokalemia
  • May be life-threatening. Monitor potassium levels in patients at risk for hypokalemia and treat if indicated.
Fluid Retention and Heart Failure With Concomitant Use of Thiazolidinediones (TZDs)
  • Thiazolidinediones (TZDs) can cause dose-related fluid retention, particularly when used in combination with insulin. Observe for signs and symptoms of heart failure and consider reduction or discontinuation if heart failure occurs.
Adverse Reactions
  • Other adverse reactions include allergic reactions, lipodystrophy, injection site reactions, pruritus, and rash.
Drug Interactions
  • Some medications may alter glucose metabolism and may necessitate insulin dose adjustment.
  • Particularly close glucose monitoring may be required when Humulin R U-500 is co-administered with drugs such as antiadrenergic agents that can alter the signs of hypoglycemia.
HM U500 HCP ISI 15NOV2019

For more information, see Full Prescribing Information, including Patient Information and Instructions for Use for the KwikPen and vial.

Humulin® and KwikPen® are registered trademarks owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates, and are available by prescription only.



© Lilly USA, LLC 2021. All rights reserved.
PP-HM-US-1972 04/2021

 


Curtis Triplitt, PharmD, CDCES
Associate Professor of Medicine, Division of Diabetes,
University of Texas Health Science Center
San Antonio, Texas

Curtis Triplitt, PharmD, CDCES, is an associate professor of medicine and a clinical assistant professor of pharmacy at the University of Texas Health Science Center in San Antonio, Texas. He earned his medical degree at the University of Texas in San Antonio and Austin. Dr. Triplitt was the 2016–2017 co-chair for the Education Committee and Scientific Sessions Planning Committee of the American Diabetes Association.

Dr. Triplitt has worked as a subinvestigator for numerous research initiatives and has been published in the American Journal of Physiology. He is a member of the American Diabetes Association and the Association of Diabetes Care and Education Specialists.




*>200 units of insulin per day.

INDICATION FOR HUMULIN® R U-500

Humulin R U-500 is a concentrated human insulin indicated to improve glycemic control in adults and children with diabetes mellitus requiring more than 200 units of insulin per day.
Limitations of Use: The safety and efficacy of Humulin R U-500 used in combination with other insulins, or when delivered by continuous subcutaneous infusion, has not been determined.

IMPORTANT SAFETY INFORMATION FOR HUMULIN R U-500

Contraindications
Humulin R U-500 is contraindicated during episodes of hypoglycemia and in patients hypersensitive to Humulin R U-500 or any of its excipients.

Hyperglycemia, Hypoglycemia, or Death Due to Dosing Errors With Vial Presentation

  • Can be life-threatening. Overdose has occurred as a result of dispensing, prescribing, or administration errors. Attention to details at all levels is required to prevent these errors.
  • Patients should be prescribed U-500 syringes for use with Humulin R U-500 vials. Do not use any other type of syringe to administer Humulin R U-500.
  • If using the Humulin R U-500 KwikPen®, patients should be counseled to dial and dose the prescribed number of units of insulin.
  • Do NOT perform dose conversion when using the Humulin R U-500 KwikPen or U-500 insulin syringe.
DO NOT transfer Humulin R U-500 from the KwikPen into any syringe for administration. Overdose and severe hypoglycemia can occur.

Never share a KwikPen or U-500 syringe between patients, even if the needle is changed, to avoid risk of transmission of blood-borne pathogens.

Hyperglycemia or Hypoglycemia With Changes in Insulin Regimen
  • Changes in insulin strength, manufacturer, type, injection site, or method of administration may affect glycemic control and predispose to hypoglycemia or hyperglycemia. Any changes in insulin regimen should be made cautiously and only under close medical supervision, and the frequency of blood glucose monitoring should be increased. Due to reports of hypoglycemia and hyperglycemia, advise patients who have repeatedly injected into areas of lipodystrophy or localized cutaneous amyloidosis to change the injection site to the unaffected areas and to closely monitor blood glucose. For patients with type 2 diabetes, dosage adjustments of concomitant anti-diabetic products may be needed.
Hypoglycemia
  • Hypoglycemia is the most common adverse reaction associated with insulin, including Humulin R U-500. Severe hypoglycemia can cause seizures, may be life-threatening, or cause death.
  • Increase monitoring with changes to insulin dosage, co-administered glucose-lowering medications, meal patterns, physical activity, and in patients with renal or hepatic impairment or hypoglycemia unawareness. To minimize risk of hypoglycemia, do not administer Humulin R U-500 intravenously, intramuscularly, or in an insulin pump or dilute or mix with other products, including other insulins.
  • Patients and caregivers must be educated to recognize and manage hypoglycemia. Self-monitoring of blood glucose plays an essential role in the prevention and management of hypoglycemia. In patients at higher risk for hypoglycemia and patients who have reduced symptomatic awareness of hypoglycemia, increased frequency of blood glucose monitoring is recommended.
Hypersensitivity and Allergic Reactions
  • Severe, life-threatening, generalized allergy, including anaphylaxis, can occur with insulin products, including Humulin R U-500. If hypersensitivity reactions occur, discontinue Humulin R U-500; treat per standard of care and monitor until symptoms and signs resolve.
Hypokalemia
  • May be life-threatening. Monitor potassium levels in patients at risk for hypokalemia and treat if indicated.
Fluid Retention and Heart Failure With Concomitant Use of Thiazolidinediones (TZDs)
  • Thiazolidinediones (TZDs) can cause dose-related fluid retention, particularly when used in combination with insulin. Observe for signs and symptoms of heart failure and consider reduction or discontinuation if heart failure occurs.
Adverse Reactions
  • Other adverse reactions include allergic reactions, lipodystrophy, injection site reactions, pruritus, and rash.
Drug Interactions
  • Some medications may alter glucose metabolism and may necessitate insulin dose adjustment.
  • Particularly close glucose monitoring may be required when Humulin R U-500 is co-administered with drugs such as antiadrenergic agents that can alter the signs of hypoglycemia.
HM U500 HCP ISI 15NOV2019

For more information, see Full Prescribing Information, including Patient Information and Instructions for Use for the KwikPen and vial.

Humulin® and KwikPen® are registered trademarks owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates, and are available by prescription only.



© Lilly USA, LLC 2021. All rights reserved.
PP-HM-US-1972 04/2021

 

This webinar is FREE for ADCES members and non-members.



*>200 units of insulin per day.

INDICATION FOR HUMULIN® R U-500

Humulin R U-500 is a concentrated human insulin indicated to improve glycemic control in adults and children with diabetes mellitus requiring more than 200 units of insulin per day.
Limitations of Use: The safety and efficacy of Humulin R U-500 used in combination with other insulins, or when delivered by continuous subcutaneous infusion, has not been determined.

IMPORTANT SAFETY INFORMATION FOR HUMULIN R U-500

Contraindications
Humulin R U-500 is contraindicated during episodes of hypoglycemia and in patients hypersensitive to Humulin R U-500 or any of its excipients.

Hyperglycemia, Hypoglycemia, or Death Due to Dosing Errors With Vial Presentation

  • Can be life-threatening. Overdose has occurred as a result of dispensing, prescribing, or administration errors. Attention to details at all levels is required to prevent these errors.
  • Patients should be prescribed U-500 syringes for use with Humulin R U-500 vials. Do not use any other type of syringe to administer Humulin R U-500.
  • If using the Humulin R U-500 KwikPen®, patients should be counseled to dial and dose the prescribed number of units of insulin.
  • Do NOT perform dose conversion when using the Humulin R U-500 KwikPen or U-500 insulin syringe.
DO NOT transfer Humulin R U-500 from the KwikPen into any syringe for administration. Overdose and severe hypoglycemia can occur.

Never share a KwikPen or U-500 syringe between patients, even if the needle is changed, to avoid risk of transmission of blood-borne pathogens.

Hyperglycemia or Hypoglycemia With Changes in Insulin Regimen
  • Changes in insulin strength, manufacturer, type, injection site, or method of administration may affect glycemic control and predispose to hypoglycemia or hyperglycemia. Any changes in insulin regimen should be made cautiously and only under close medical supervision, and the frequency of blood glucose monitoring should be increased. Due to reports of hypoglycemia and hyperglycemia, advise patients who have repeatedly injected into areas of lipodystrophy or localized cutaneous amyloidosis to change the injection site to the unaffected areas and to closely monitor blood glucose. For patients with type 2 diabetes, dosage adjustments of concomitant anti-diabetic products may be needed.
Hypoglycemia
  • Hypoglycemia is the most common adverse reaction associated with insulin, including Humulin R U-500. Severe hypoglycemia can cause seizures, may be life-threatening, or cause death.
  • Increase monitoring with changes to insulin dosage, co-administered glucose-lowering medications, meal patterns, physical activity, and in patients with renal or hepatic impairment or hypoglycemia unawareness. To minimize risk of hypoglycemia, do not administer Humulin R U-500 intravenously, intramuscularly, or in an insulin pump or dilute or mix with other products, including other insulins.
  • Patients and caregivers must be educated to recognize and manage hypoglycemia. Self-monitoring of blood glucose plays an essential role in the prevention and management of hypoglycemia. In patients at higher risk for hypoglycemia and patients who have reduced symptomatic awareness of hypoglycemia, increased frequency of blood glucose monitoring is recommended.
Hypersensitivity and Allergic Reactions
  • Severe, life-threatening, generalized allergy, including anaphylaxis, can occur with insulin products, including Humulin R U-500. If hypersensitivity reactions occur, discontinue Humulin R U-500; treat per standard of care and monitor until symptoms and signs resolve.
Hypokalemia
  • May be life-threatening. Monitor potassium levels in patients at risk for hypokalemia and treat if indicated.
Fluid Retention and Heart Failure With Concomitant Use of Thiazolidinediones (TZDs)
  • Thiazolidinediones (TZDs) can cause dose-related fluid retention, particularly when used in combination with insulin. Observe for signs and symptoms of heart failure and consider reduction or discontinuation if heart failure occurs.
Adverse Reactions
  • Other adverse reactions include allergic reactions, lipodystrophy, injection site reactions, pruritus, and rash.
Drug Interactions
  • Some medications may alter glucose metabolism and may necessitate insulin dose adjustment.
  • Particularly close glucose monitoring may be required when Humulin R U-500 is co-administered with drugs such as antiadrenergic agents that can alter the signs of hypoglycemia.
HM U500 HCP ISI 15NOV2019

For more information, see Full Prescribing Information, including Patient Information and Instructions for Use for the KwikPen and vial.

Humulin® and KwikPen® are registered trademarks owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates, and are available by prescription only.



© Lilly USA, LLC 2021. All rights reserved.
PP-HM-US-1972 04/2021

Test Your Computer

To ensure that your participation is successful, please test your system as soon as possible so if you do have technical challenges, you will have time to get them sorted out. Click here to test your computer.

System Requirements

While you can participate with a 56K dialup internet connection, it is recommended that you have a high-speed broadband (or better) internet connection. Please be sure you close as many open programs on your system as possible. Click here for operating system requirements.



*>200 units of insulin per day.

INDICATION FOR HUMULIN® R U-500

Humulin R U-500 is a concentrated human insulin indicated to improve glycemic control in adults and children with diabetes mellitus requiring more than 200 units of insulin per day.
Limitations of Use: The safety and efficacy of Humulin R U-500 used in combination with other insulins, or when delivered by continuous subcutaneous infusion, has not been determined.

IMPORTANT SAFETY INFORMATION FOR HUMULIN R U-500

Contraindications
Humulin R U-500 is contraindicated during episodes of hypoglycemia and in patients hypersensitive to Humulin R U-500 or any of its excipients.

Hyperglycemia, Hypoglycemia, or Death Due to Dosing Errors With Vial Presentation

  • Can be life-threatening. Overdose has occurred as a result of dispensing, prescribing, or administration errors. Attention to details at all levels is required to prevent these errors.
  • Patients should be prescribed U-500 syringes for use with Humulin R U-500 vials. Do not use any other type of syringe to administer Humulin R U-500.
  • If using the Humulin R U-500 KwikPen®, patients should be counseled to dial and dose the prescribed number of units of insulin.
  • Do NOT perform dose conversion when using the Humulin R U-500 KwikPen or U-500 insulin syringe.
DO NOT transfer Humulin R U-500 from the KwikPen into any syringe for administration. Overdose and severe hypoglycemia can occur.

Never share a KwikPen or U-500 syringe between patients, even if the needle is changed, to avoid risk of transmission of blood-borne pathogens.

Hyperglycemia or Hypoglycemia With Changes in Insulin Regimen
  • Changes in insulin strength, manufacturer, type, injection site, or method of administration may affect glycemic control and predispose to hypoglycemia or hyperglycemia. Any changes in insulin regimen should be made cautiously and only under close medical supervision, and the frequency of blood glucose monitoring should be increased. Due to reports of hypoglycemia and hyperglycemia, advise patients who have repeatedly injected into areas of lipodystrophy or localized cutaneous amyloidosis to change the injection site to the unaffected areas and to closely monitor blood glucose. For patients with type 2 diabetes, dosage adjustments of concomitant anti-diabetic products may be needed.
Hypoglycemia
  • Hypoglycemia is the most common adverse reaction associated with insulin, including Humulin R U-500. Severe hypoglycemia can cause seizures, may be life-threatening, or cause death.
  • Increase monitoring with changes to insulin dosage, co-administered glucose-lowering medications, meal patterns, physical activity, and in patients with renal or hepatic impairment or hypoglycemia unawareness. To minimize risk of hypoglycemia, do not administer Humulin R U-500 intravenously, intramuscularly, or in an insulin pump or dilute or mix with other products, including other insulins.
  • Patients and caregivers must be educated to recognize and manage hypoglycemia. Self-monitoring of blood glucose plays an essential role in the prevention and management of hypoglycemia. In patients at higher risk for hypoglycemia and patients who have reduced symptomatic awareness of hypoglycemia, increased frequency of blood glucose monitoring is recommended.
Hypersensitivity and Allergic Reactions
  • Severe, life-threatening, generalized allergy, including anaphylaxis, can occur with insulin products, including Humulin R U-500. If hypersensitivity reactions occur, discontinue Humulin R U-500; treat per standard of care and monitor until symptoms and signs resolve.
Hypokalemia
  • May be life-threatening. Monitor potassium levels in patients at risk for hypokalemia and treat if indicated.
Fluid Retention and Heart Failure With Concomitant Use of Thiazolidinediones (TZDs)
  • Thiazolidinediones (TZDs) can cause dose-related fluid retention, particularly when used in combination with insulin. Observe for signs and symptoms of heart failure and consider reduction or discontinuation if heart failure occurs.
Adverse Reactions
  • Other adverse reactions include allergic reactions, lipodystrophy, injection site reactions, pruritus, and rash.
Drug Interactions
  • Some medications may alter glucose metabolism and may necessitate insulin dose adjustment.
  • Particularly close glucose monitoring may be required when Humulin R U-500 is co-administered with drugs such as antiadrenergic agents that can alter the signs of hypoglycemia.
HM U500 HCP ISI 15NOV2019

For more information, see Full Prescribing Information, including Patient Information and Instructions for Use for the KwikPen and vial.

Humulin® and KwikPen® are registered trademarks owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates, and are available by prescription only.



© Lilly USA, LLC 2021. All rights reserved.
PP-HM-US-1972 04/2021

Share with friends: